Cholesteryl Ester Transfer Protein Inhibitors and Access to the Retina in Age-Related Macular Degeneration—Reply

Authors:
Publisher website
Google Scholar
Abstract
In Reply We appreciate the thoughtful comments from Curcio and Johnson, which have added to our knowledge of the mechanisms of transport within the eye and particularly across the Bruch membrane. If it is true that cholesteryl ester transfer protein (CETP) inhibitors bound to high-density lipoprotein particles can pass the Bruch membrane, this emphasizes the possible risk of age-related macular degeneration (AMD) as an adverse effect to treatment with CETP inhibitors.1 This contrasts with what has been suggested by Tall et al,2 and consequently, when conducting randomized clinical trials in the future, examining participants for AMD as a potential adverse effect to pharmacological CETP inhibition will be of utmost importance. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.